Acute Myeloid Leukemia-Targeted Toxin Activates Both Apoptotic and Necroptotic Death Mechanisms by Horita, Henrick et al.
Acute Myeloid Leukemia-Targeted Toxin Activates Both
Apoptotic and Necroptotic Death Mechanisms
Henrick Horita
1, Arthur E. Frankel
2, Andrew Thorburn
1*
1Department of Pharmacology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States of America, 2Scott & White Cancer Research Institute,
Temple, Texas, United States of America
Abstract
Background: Acute myelogenous leukemia (AML) is the second most common leukemia with approximately 13,410 new
cases and 8,990 deaths annually in the United States. A novel fusion toxin treatment, diphtheria toxin GM-CSF (DT-GMCSF)
has been shown to selectively eliminate leukemic repopulating cells that are critical for the formation of AML. We previously
showed that DT-GMCSF treatment of U937 cells, an AML cell line, causes activation of caspases and the induction of
apoptosis.
Methods and Findings: In this study we further investigate the mechanisms of cell death induced by DT-GMCSF and show
that, in addition to the activation of caspase-dependent apoptosis, DT-GMCSF also kills AML cells by simultaneously
activating caspase-independent necroptosis. These mechanisms depend on the ability of the targeted toxin to inhibit
protein synthesis, and are not affected by the receptor that is targeted or the mechanism through which protein synthesis is
blocked.
Conclusions: We conclude that fusion toxin proteins may be effective for treating AML cells whether or not they are
defective in apoptosis.
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Introduction
Acute myelogenous leukemia (AML) is the second most common
leukemia with approximately 13,410 new cases annually in the
UnitedStates and 8,990 deathseach year[1]. Current treatment for
AML is the anti-metabolite cytosine arabinoside and anthracycline,
which results in 65–85% of patients achieving complete clinical
response [2,3]. Unfortunately, most of these patients succumb to
new tumors [2] because cytosine arabinoside does not effectively
target the critical tumor progenitor cells, which allows the tumor to
reappear over time. Thus, new therapies are needed to effectively
target these long-term leukemic repopulating cells in order to
eradicate AML. Granulocyte-Macrophage Colony-Stimulating
Factor Receptors (GM-CSFR) are upregulated in many AMLs
[4], and more than 70% of AMLs respond to Granulocyte-
Macrophage Colony-Stimulating Factor (GM-CSF) [5]. Thus, one
potential approach for more effectively treating AML would be to
selectively target cells with increased levels of GM-CSFR. A novel
fusion toxin treatment, diphtheria toxin GM-CSF (DT-GMCSF)
has been shown to eliminate these long-term leukemic repopulating
cells while sparing normal hemopoietic cells [4,6].
Targeted toxins are fusion proteins that combine a targeting
protein, such as a ligand for a specific receptor, and a toxic peptide
derived from a bacterial pathogen [7,8]. Diphtheria toxin (DT) is a
bacterial pathogen that kills eukaryotic cells by inhibiting protein
synthesis through the ADP-ribosylation of eEF-2 [9]. Previous
studies from our groups show that a recombinant fusion protein
consisting of DT-GMCSF selectively kills AML cells [10]. We
previously showed that DT-GMCSF treatment of U937 cells, an
AML cell line, causes activation of caspases and the induction of
apoptosis [10] via a mechanism that involved the adaptor protein
FADD, which regulates the extrinsic apoptotic pathway that is
normally activated by ligand binding to death receptors (e.g. Fas/
CD95 and the TRAIL receptors). However, because tumor cells
often develop resistance to apoptosis e.g. by loss of caspases,
upregulation of anti-apoptotic Bcl-2 family proteins or through
increased expression of caspase inhibitors, we wished to test if
other mechanisms of cell killing could also be induced in AML
cells treated with DT-GMCSF. One potential mechanism through
which this might be achieved is a novel caspase-independent cell
death mechanism that utilizes components of the extrinsic
apoptosis pathway to induce a programmed necrotic cell death
mechanism that has been termed necroptosis [11,12].
We show that DT-GMCSF kills AML cells by simultaneously
activating both caspase dependent apoptosis and caspase-inde-
pendent necroptosis. Because targeted toxins also activate the
receptors that they are targeted through and these signals might
regulate the death mechanisms, we also tested whether the native
DT protein and the chemical protein synthesis inhibitor
cycloheximide work through the same mechanisms. We conclude
that fusion toxin proteins may be effective for treating AML cells
whether or not they are defective in apoptosis because they can
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apoptosis. These mechanisms depend on the ability to inhibit
protein synthesis, not the receptor that is targeted or the
mechanism through which protein synthesis is blocked.
Results
DT-GMCSF Reduces Anti-Apoptotic Proteins and
Activates Apoptosis
Previous studies in our laboratory indicated that DT-GMCSF
can activate caspases in U937 cells [10]. Because diphtheria toxin
is a potent inhibitor of protein synthesis, this may be associated
with the downregulation of anti-apoptotic proteins with rapid
turnover, such as, the caspase inhibitor XIAP. To confirm these
conclusions and test the functional significance of the apoptosis,
U937 cells were exposed to increasing doses of DT-GMCSF for
48 hours and cell survival was determined with a MTS cell
viability assay (Fig. 1A). Consistent with the idea that this cell
death is associated with apoptotic characteristics, chromatin was
digested into a nucleosomal ladder (data not shown). Western blot
analysis showed that 150 ng/ml of DT-GMCSF causes a marked
decrease in XIAP levels (Fig. 1B), which supports the notion that
DT-GMCSF reduces anti-apoptotic proteins and can activate
caspase-dependent apoptosis. If caspase activation and apoptosis is
the mechanism of DT-GMCSF-induced death, caspase inhibition
should protect against the drug. However, pre-treatment with the
pan-caspase inhibitor zVADfmk at 50 mM provided only partial
protection against DT-GMCSF induced cell death (Fig. 1C).
These data indicate that caspase-independent, non-apoptotic
mechanisms also contribute to the DT-GMCSF-induced death.
DT-GMCSF Activates Necroptosis as an Additional Death
Mechanism
Our previous data indicated that DT-GMCSF induced cell
death was dependent on the adaptor protein FADD [10].
Therefore, we hypothesized that the caspase-independent death
mechanism might arise through a process that is also induced by
components of the extrinsic pathway. Yuan and colleagues
characterized another cell death pathway activated by TNF2a
when caspases were inhibited, which they termed necroptosis. This
alternative cell death pathway utilizes FADD to recruit the protein
kinase RIP to execute a non-caspase-dependent death signal
[13,14]. Additionally, they identified a specific inhibitor to this
form of cell death called Necrostatin-1 (NEC-1) [11]. To test if
necroptosis contributes to the DT-GMCSF-induced death, we
pre-treated cells with the caspase inhibitor zVADfmk and NEC-1
separately and together and asked if the combination of inhibitors
was more effective than either alone. DT-GMCSF induced cell
death was more effectively inhibited by the combination of
inhibitors (Fig. 2A) suggesting that necroptosis contributes to the
caspase-independent death.
Inhibition of RIP Protects Against DT-GMCSF
If DT-GMCSF activates necroptosis, then we should be able to
recapitulate protection against DT-GMCSF seen with NEC-1 by
removing RIP, which interacts with FADD [11,13] and is required
for necroptosis [11]. We therefore used geldanamycin, which
inhibits HSP70-mediated RIP stabilization [15] to down-regulate
RIP expression (Fig. 2B). Geldanamycin alone protected against
DT-GMCSF induced cell death (Fig. 2C) and combining
geldanamycin with zVADfmk provided increased protection.
Inhibition of cell death was not due to a down regulation of
FADD as geldanamycin did not affect FADD levels (Fig. 2B).
These data suggest that NEC-1 and geldanamycin both protect
against DT-GMCSF induced cell death by inhibiting necroptosis,
the non apoptotic death mechanism.
Diphtheria Toxin Alone is Sufficient to Activate Both Cell
Death Pathways
DT-GMCSF utilizes the GMCSF receptor to target AML cells,
and we previously showed that this leads to activation of GMCSF
Receptor signaling {Horita, 2008 #1449}{Thorburn, 2004
#1191}, which activates various survival and proliferative
pathways that can result in upregulation of anti-apoptotic proteins
[17]. It is therefore possible that inhibition of the apoptotic
pathway as a consequence of the receptor activation may force the
tumor cells to die by activation of the alternative necroptotic
pathway. To test this hypothesis, we asked if the diphtheria toxin
portion of the drug is sufficient to activate both cell death
pathways, or alternatively if signaling through the GMCSF
receptor determines which pathways are activated. We treated
U937 cells with native diphtheria toxin obtaining dose-dependent
cell death similar to DT-GMCSF treatment (Fig. 3A). We detected
caspase 3 and 7 activity with diphtheria toxin treatment that
mimicked those seen with DT-GMCSF (Fig. 3B). We also
observed distinct nucleosomal laddering as a result of chromatin
digestion when we treated cells with diphtheria toxin at 150 ng/
ml, which is similar to U937 cells that have been treated with the
bona fide activator of the extrinsic apoptosis pathway TRAIL
(Fig. 3C). These data suggest that diphtheria toxin alone is
sufficient to activate the apoptosis pathway in U937 cells.
However, as with DT-GMCSF, addition of NEC-1 alone or in
combination with zVADfmk provided significant protection
against diphtheria toxin induced cell death (Fig. 3D) indicating
that the toxin activates both cell death mechanisms regardless of
GMCSF receptor activation.
Inhibition of Protein Synthesis is Sufficient to Activate
Apoptosis and Necroptosis in U937 Cells
Diphtheria toxin ADP-ribosylates eEF-2 to shut down protein
synthesis and an ADP-ribosylation inhibitor completely blocked
targeted toxin induced cell death (data not shown). We therefore
asked if another mechanism of protein synthesis inhibition is
sufficient to activate apoptosis and necroptosis by treating cells
with high levels (5 mg/ml) of cycloheximide (a chemical inhibitor
of protein synthesis that works by interfering with the 80S
ribosome), which as with DT-GMCSF significantly decreased
XIAP levels in U937cells (data not shown). Cycloheximide
induced effector caspase activity similar to that observed with
DT-GMCSF and diphtheria toxin treatment (Fig. 4A). These data
indicate that inhibition of protein synthesis is sufficient to induce
caspase-dependent apoptosis in U937 cells. Moreover, similar to
DT-GMCSF, pre-treatment with zVADfmk alone was not able to
provide complete protection against cell death (Fig. 4B), while
addition of NEC-1 (Fig. 4B) or RIP depletion with geldanomycin
(Fig. 4C) provided additional protection. These data suggest that
any mechanism of inhibiting protein synthesis activates both
apoptosis and necroptosis in these cells.
Necrostatin Protects Against DT-GMCSF in Other AML
cell Lines
We next asked whether DT-GMCSF’s ability to activate
necroptosis occurs in other AML cell types. Treatment of Kusami
cells (Fig. 5A) and HL60 cells (Fig. 5D) with DT-GMCSF showed
that the drug also killed these AML cell lines (although to a lesser
extent than the U937 cells). We then measured caspase activity in
both cell lines treated with DT-GMCSF and found similar
Targeted Toxin-Induced Death
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treated cells with DT-GMCSF in the presence of zVADfmk and
NEC-1. Interestingly, both cell types had increased viability in the
presence of NEC-1, however, there was little protection with
zVADfmk (Fig. 5C,F). These data suggest that the necroptosis
pathway is activated along with the apoptosis pathway in other
AML cell lines by DT-GMCSF and emphasize that inhibition of
caspase activity doesn’t necessarily lead to protection.
Discussion
As with other anti cancer agents, better understanding of how
targeted toxins kill tumor cells may provide valuable insights to
optimize their clinical use. Previous data from our laboratory [10]
and others (reviewed in [18]) showed that, like many other anti-
cancer agents, targeted fusion toxin proteins often kill tumor cells
by activating caspase dependent apoptosis. In this study we extend
these findings to show that in addition to caspase-dependent
apoptosis, a targeted or native DT protein and a chemical
inhibitor of protein synthesis also kill AML cells by activating
necroptosis, which is a non-apoptotic programmed cell death
mechanism that requires the protein kinase RIP. In U937 cells,
both mechanisms contribute similarly to cell death because
selective inhibition of necroptosis with NEC-1 or depletion of
RIP provided some protection, which was increased by addition of
a caspase inhibitor. However, in other cell types the protection by
necrostatin was greater than that provided by the caspase
inhibitor. The mechanism of action of DT-GMCSF is dependent
on the diphtheria toxin and inhibition of protein synthesis alone, as
both native DT and cycloheximide were sufficient to activate both
cell death mechanisms similarly to DT-GMCSF. This leaves us
with the question of how protein synthesis inhibition activates both
apoptotic and non-apoptotic cell death mechanisms. For apopto-
sis, depletion of proteins with rapid turn-over that directly inhibit
the apoptosis machinery, such as, XIAP provides a plausible
explanation and we suggest that the necroptosis machinery may
also be held in check by inhibitors that are depleted in cells where
protein synthesis is blocked.
Although DT-GMCSF can kill AML cells in both an apoptotic
and necroptotic fashion, blocking these two pathways may only
delay the death as shown by lesser protection at later time points
(Figure 2A). Additionally, we previously found that certain cell
lines that don’t activate caspases at all in response to targeted DT
may die by a slow cell death mechanism that does not involve the
release of cytosolic proteins that occurs in necroptosis [16,19].
Together, these findings indicate that despite the fact that targeted
DT fusion toxins work by inhibiting a fundamental cell activity
(protein synthesis), multiple death mechanisms can be activated
that may be more or less important depending upon the particular
tumor cell that is being targeted. Thus, although our data clearly
show that many tumor cells die in response to targeted toxins by
activating efficient and rapid death pathways such as necroptosis
or apoptosis, the drugs may be effective even if these pathways are
blocked. In fact, we have found that the most effective ways to
block targeted DT proteins from killing tumor cells effectively
enough, so that tumor cells can regain the capacity for clonogenic
growth after removal of the toxin, is by preventing drug uptake by
depleting target signaling receptor [19] or by inhibiting the
catalytic subunit of diphtheria toxin using an ADP-ribosylation
inhibitor (unpublished data). These data suggest that unlike with
some other tumor-selective agents such as TRAIL receptor-
targeted drugs, where true resistance can be achieved by inhibiting
apoptosis [20], it may be more difficult for tumor cells to evolve a
mechanism of avoiding targeted toxin-induced death.
DT-GMCSF has shown clinical efficacy when used to treat
patients with AML, however, it also caused liver toxicity due to
GMCSF receptor expression in monocytes and macrophages [21–
23]. It may be possible to avoid the toxicity problems using a
modified version of DT-GMCSF (DTU2GMCSF) that provides
dual targeting specificity to AML cells by replacing the furin
cleavage site within the toxin with a urokinase plaminogen
activator (uPA) cleavage site [22,23]. Other fusion toxin drugs
utilizing diphtheria toxin, e.g. DT-IL3, are also being tested in
clinical trials to treat AML [24]. Our data show that the diphtheria
toxin subunit is responsible for the type of cell death induced in
AML cells, thus these other drugs that incorporate diphtheria
toxin should work by a similar mechanism to DT-GMCSF.
Therefore, we anticipate that the multiple death mechanisms that
we have observed will be induced by these agents and that our
arguments about the difficulty of evolving true resistance to these
drugs will also apply to these different targeted toxins.
In summary, we show that at least two programmed cell death
mechanisms (apoptosis and necroptosis) are activated by GMCSF-
targeted diphtheria toxin in AML cells. Consistent with previous
studies using other toxins in different cell types, the particular
pathway that is activated depends, to at least some extent, on the
cell line that is being tested, however the most important finding is
that blocking any one death mechanism is not sufficient to prevent
tumor cell killing, and instead just causes the cell to die from the
other mechanism or by slower death pathway. In the clinical
context we propose that these attributes will make it difficult for
tumor cells to evolve resistance mechanisms other than down-
regulation of the targeted receptor. Since the receptors that are
targeted with this approach are usually chosen because they are
important for driving tumor growth, one would expect selective
pressure against downregulation of the receptor, which should
increase the efficacy of the treatment if a useful therapeutic
window can be developed by avoiding targeting normal tissues.
Therefore, our data also emphasize that the practical application
of targeted toxins in the clinic will require that we are successful in
our efforts to make the tumor targeting as selective as possible
and/or using delivery methods that are able to avoid susceptible
normal tissues.
Materials and Methods
Reagents. Human U937 cells, Kusami and HL60 cells were
obtained from American Type Culture collection and maintained
in RPMI 1640 growth medium (HyClone, Logan, UT)
supplemented with 10% fetal bovine serum (FBS) (HyClone,
Logan, UT) in a 5% CO2 humidified atmosphere at 37uC. DT-
GMCSF was prepared as described previously [13]. Unless
otherwise noted, chemicals and reagents were obtained from
Sigma Chemical Co. (St. Louis, MO). Cycloheximide at 5 mg/ml,
geldanamycin (Alexis Biochemicals, San Diego, CA) at 0.5 mM,
1 mM, or 2 mM, zVADfmk (Alexis Biochemicals, San Diego, CA)
Figure 1. DT-GMCSF reduces anti-apoptotic proteins and activates apoptosis. (A). Cell viability of U937 cells as determined by MTS assays
after 48 hours of treatment with DT-GMCSF 3-fold serial dilution (mean+/2SEM from 3 replicates). (B). Analysis of X-IAP protein levels in U937 cells in
response to DT-GMCSF for 12 hours by western blotting. (C). Pre-treatment with zVADfmk (50 mM) for one hour protects U937 cells against DT-
GMCSF (150 ng ml
21) toxicity as determined by MTS assays (mean+/2SEM from 3 replicates) (*P,0.05).
doi:10.1371/journal.pone.0003909.g001
Targeted Toxin-Induced Death
PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e3909Figure 2. DT-GMCSF activates necroptosis as an additional death mechanism. (A). MTS assays quantifying cell viability of U937 cells in
response to DT-GMCSF (150 ng ml
21) in the presence of Necrostation-1 (50 mM) alone or in combination with zVADfmk (50 mM) (mean+/2SEM from
4 replicates). (B). Western blotting for RIP in the presence of the HSP90 inhibitor Geldanamycin at increasing concentrations. Geldanamycin
specifically depletes RIP levels while not affecting other proteins important for apoptotic and necrotic cell death such as FADD. (C). Pre-treatment
with Geldanamycin (0.5 mM) either alone or in combination with zVADfmk (25 mM) protects U937 cells against DT-GMCSF induced cell death as
determined by MTS assays (mean+/2SEM from 3 replicates) (* P,0.05) (**P,0.01) (#P,0.005) (##P,0.001).
doi:10.1371/journal.pone.0003909.g002
Targeted Toxin-Induced Death
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Plymouth Meeting, PA) at 50 mM, diphtheria toxin
(Calbiochem, La Jolla, CA), TRAIL (R&D Systems, Inc.,
Minneapolis, MN) at 150 ng/ml.
Immunoblotting. At the indicated times, 1610
6 cells were
harvested, and lysates were prepared by boiling in SDS buffer
10 minutes prior to gel electrophoresis. Lysates were resolved on
12% SDS-polyacrylamide gels. Following electrophoresis, proteins
were transferred to nitrocellulose membrane. Blots were incubated
with antibodies that recognize X-IAP (Cell Signaling
Technologies, Danvers, MA), RIP (BD Pharmigen), and FADD
(BD Pharmigen ), and b-Actin (Sigma, St Louis, MO). Blots were
then incubated with anti-rabbit or anti-mouse horseradish
peroxidase-conjugated secondary antibodies (Cell Signaling
Technologies, Danvers, MA). Detection was performed using the
chemiluminescent ECL reagent (Millipore Corporation, Billerica,
MA), and developed on Blue Basic Autorad Film (ISC Bioexpress,
Kaysville, UT).
DNA Laddering. At the indicated times, 1610
6 cells were
pelleted at 900 g for 5 minutes. The supernatant was discarded
and pellets were washed with PBS. Cells were then resuspended in
SDS lysis buffer (add fresh 0.5 mg/ml proteinase K) and
incubated at 55uC for one hour. Cell debris were pelleted and
removed. 5 ml of RNase A were then added (1 mg/ml) to the
supernatant and incubated at 55uC for one hour. The samples
were next incubated at 80uC for 20 minutes to inactivate the
proteinase K. 15 mL of sample were loaded on a 2% agarose gel
(0.5 mg/ml ethidium bromide) and visualized with UV
transillumination on a Molecular Imager Gel Doc XR system
(Bio-Rad Laboratories, Hercules, CA).
Caspase 3/7 Activity. Cells were plated in a 96 well black-
walled plate at a concentration of 30,000 cells per well. Drugs were
added in triplicate at timepoints of interest. One hour prior to the
end of assay Caspase-Glo 3/7 reagent (Promega, Madison, WI)
was added to each well at a 1:1 ratio according to manufacturers’
instructions. Cells were then incubated in the dark for one hour.
Samples were measured using a Veritas microplate luminometer
(Turner BioSystems, Sunnyvale, CA).
MTS cell viability. Cells were plated in a 96 well format at
30,000 cells per well and treated with the indicated drugs in
triplicate wells. One hour prior to the end of the experiment cells
were treated with 20 ml of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt (MTS) (Promega, Madison, WI) according to manufacturers’
instructions and measured with a Bio-Rad Benchmark Plus
Microplate Spectrophotometer (Bio-Rad Laboratories, Hercules,
CA) at an absorbance value of 490 nm. For samples where
inhibitors (NEC-1, geldanamycin etc.) were used, normalization to
control cells treated with the inhibitor alone was carried out to
account for any toxicity caused by the inhibitor itself.
Figure 3. Diphtheria toxin alone is sufficient to activate both cell death pathways (mean+/2SEM from 3 replicates). (A). MTS assays
measuring U937 cell viability in response to Diphtheria toxin dose curve. (mean+/2SEM from 3 replicates) (B). Diphtheria toxin (150 ng ml
21)
activates caspases in U937 cells as determined using a caspase 3/7 specific luminogenic substrate (mean+/2SEM from 3 replicates). (C) DNA from
U937 cells treated with Diphteria toxin (150 ng ml
21) or TRAIL (150 ng ml
21)/cycloheximide (0.5 mg/ml) were run on a 2% agarose gel to detect
nucleosomal laddering as a marker of apoptosis. (D). Pretreating U937 cells with zVADfmk (50 mM) and/or Necrostatin-1 (50 mM) provides protection
against Diphtheria toxin (150 ng ml




PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3909Figure 4. Inhibition of protein synthesis is sufficient to activate apoptosis and necroptosis in U937 cells. (A). Cycloheximide (5 mgm l
21)
induce caspase activity in U937 cells in a manner similar to both Diphtheria toxin and DT-GMCSF as determined using a caspase 3/7 luminogenic
assay (mean+/2SEM from 3 replicates). (B). Cell viability of U937 cells in response to cycloheximide (5 mgm l
21) in the presence of zVADfmk (50 mM)
and/or Necrostatin-1 (50 mM) was measured using MTS assays (mean+/2SEM from 4 replicates). (C). MTS assays were used to measure the ability of
Geldanamycin (0.5 mM) and zVADfmk (25 mM) to protect against cycloheximide (5 mgm l
21) induced cell death in U937 cells (mean+/2SEM from 3
replicates) (* P,0.05) (**P,0.01) (#P,0.005) (##P,0.001).
doi:10.1371/journal.pone.0003909.g004
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PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e3909Figure 5. DT-GMCSF kills other AML cells by necroptosis. (A). Cell viability of Kusami cells as determined by MTS assays after 48 hours of
treatment with DT-GMCSF 3-fold serial dilution (mean+/2SEM from 3 replicates). (B). DT-GMCSF (450 mgm l
21) induce caspase activity in Kusami cells
as determined using a caspase 3/7 luminogenic assay (mean+/2SEM from 3 replicates). (C). Cell viability of Kusami cells in response to DT-GMCSF
(450 mgm l
21) in the presence of zVADfmk (50 mM) and/or Necrostatin-1 (50 mM) was measured using MTS assays (mean+/2SEM from 3 replicates).
(D). Cell viability of HL60 cells as determined by MTS assays after 48 hours of treatment with DT-GMCSF 3-fold serial dilution (mean+/2SEM from 3
replicates). (E). DT-GMCSF (450 mgm l
21) induce caspase activity in HL60 cells as determined using a caspase 3/7 luminogenic assay (mean+/2SEM
from 3 replicates). (F). Cell viability of HL60 cells in response to DT-GMCSF (450 mgm l
21) in the presence of zVADfmk (50 mM) and/or Necrostatin-1
(50 mM) was measured using MTS assays (mean+/2SEM from 3 replicates). (* P,0.05).
doi:10.1371/journal.pone.0003909.g005
Targeted Toxin-Induced Death
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